At the beginning of 2022, BioPhorum Drug Substance leadership initiated a strategic review. It recognized that while the drug substance environment had evolved since the pandemic, the current program of workstreams had remained largely static and pre-dated many leadership team members.
From this review, it identified a shared vision, common goals, and the key trends to address over the next five to ten years – all published in this paper.
The Framework will enable the Phorum to evaluate the current program and future ideas using a common language within a consistent Framework that will support decision-making.
It includes three ‘true north’ goals:
- To make Pharma 4.0 a reality for biomanufacturing commercial operations
- To halve the time to implement post-approval changes globally
- To reduce major health authority inspection findings to zero.
However, this is just the starting point, as the real value to BioPhorum and its members will come from the insights gained from having this Framework in place. Its design facilitates the assessment of progress against agreed objectives at different levels, from the true north goals down to detailed impacts.
This is where BioPhorum is uniquely placed to excel – helping member companies resolve their combined, highest-priority issues and driving appropriate, synchronized change to create value across the industry.